Neural Activations During Imaginal Exposure in Individuals Fearful of Spiders

May 29, 2019 updated by: Uppsala University

This study explores the brain basis of imaginal exposure, a widely used psychological treatment technique. Specifically, this study uses functional magnetic resonance imaging to examine brain areas activated during imaginal exposure, in individuals fearful of spiders. Physiological responses and subjective fear experienced during imaginal exposure are also assessed.

The primary aim of this study is to explore differences in neural activity during exposure to phobic, compared to neutral, mental imagery. The study will focus primarily on exploratory whole brain analyses, but will also include regions of interest analyses on brain areas previously associated with imaginal exposure. The experimental procedure consists of repeated exposure to mental imagery, i.e. imagery of short durations, including either highly emotion-provoking or neutral content, prompted by verbal instructions. A secondary aim is to explore the effects of repeated exposure to mental imagery, used during the experimental procedure, on subjective fear and physiological responses.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Results will elucidate if neural activity to phobic imagery differs from activity associated with the production of mental imagery per se. Findings will also increase our general understanding of the neural basis of imaginal exposure treatments.

Study Type

Interventional

Enrollment (Actual)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Uppsala, Sweden
        • Uppsala University Hospital - Akademiska sjukhuset
      • Uppsala, Sweden
        • Uppsala University, Departement of Psychology

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Significant fear of spiders

Exclusion Criteria:

  • Current psychiatric disorder other than spider phobia
  • Substance abuse
  • Neurological disease
  • Psychological treatment or psychotropic medication within six months
  • Magnetic resonance imaging contradiction

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Imaginal exposure
The experimental procedure consists of imaginal exposure to mental imagery of phobic and neutral stimuli, prompted through recorded verbal instructions. Participants' repeat the experimental procedure one week later in a follow-up session. Brain imaging data is only collected during day 1
Imaginal exposure to mental imagery of phobic and neutral stimuli

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Blood oxygen level dependent contrast (BOLD-signal)
Time Frame: Day 1
BOLD-signal is assessed using functional magnetic resonance imaging.
Day 1
Physiological response during exposure to mental imagery
Time Frame: Day 1
Skin-conductance responses are used as a measure of physiological response.
Day 1

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Physiological response during exposure to mental imagery
Time Frame: Follow-up (one week after day 1)
Skin-conductance responses are used as a measure of physiological response.
Follow-up (one week after day 1)
Differences in physiological response during exposure to mental imagery, during day 1 compared to the follow-up session.
Time Frame: Difference between day 1 and the follow-up session (one week after day 1)
Skin-conductance responses are used as a measure of physiological response.
Difference between day 1 and the follow-up session (one week after day 1)
Ratings of subjective fear participants' expect to experience during exposure to mental imagery
Time Frame: Day 1
Scale: 0-100; no fear at all - extreme fear.
Day 1
Ratings of subjective fear experienced during exposure to mental imagery
Time Frame: Day 1
Scale: 0-100; no fear at all - extreme fear. Fear ratings are completed immediately after the imaginal exposure experimental procedure
Day 1
Spielberger State-Trait Anxiety Inventory (STAI-S)
Time Frame: Day 1
STAI-S is a self-rated questionnaire included to assess state-anxiety experienced during exposure. High scores indicate high levels of state anxiety (range, total score: 20 - 80).
Day 1
Differences in ratings of subjective fear during exposure to mental imagery, during day 1 compared to the follow-up session.
Time Frame: Difference between day 1 and the follow-up session (one week after day 1)
Scale: 0-100; no fear at all - extreme fear.
Difference between day 1 and the follow-up session (one week after day 1)
Vividness of mental imagery
Time Frame: Day 1
Vividness of mental imagery of phobic stimuli (scale: 1-5; no image at all - image as clear and vivid as real life).
Day 1
Vividness of mental imagery
Time Frame: Follow-up (one week after day 1)
Vividness of imagery of phobic stimuli (scale: 1-5; no image at all - image as clear and vivid as real life).
Follow-up (one week after day 1)
Differences in vividness of mental imagery, during day 1 compared to the follow-up session.
Time Frame: Difference between day 1 and the follow-up session (one week after day 1)
Vividness of imagery of phobic stimuli (scale: 1-5; no image at all - image as clear and vivid as real life).
Difference between day 1 and the follow-up session (one week after day 1)
Difficulties in emotion regulation scale (DERS)
Time Frame: Day 1
DERS is a self-rated questionnaire, included to explore potential relations between imaginal exposure and difficulties in emotion regulation. High scores indicate more difficulties in emotion regulation (range, total score: 36 - 180)
Day 1

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Spider Phobia Questionnaire (SPQ)
Time Frame: Recruitment
SPQ is a self-rated questionnaire assessing fear of spiders. A high score in SPQ (>19) is required for inclusion in the study.
Recruitment
Spielberger State-Trait Anxiety Inventory (STAI-T)
Time Frame: Day 1
STAI-T is a self-rated questionnaire assessing trait anxiety and is included to describe the sample in terms of anxiety proneness. High scores indicate higher levels of trait anxiety (range, total score: 20 - 80)
Day 1
Number of intrusive mental imagery of phobic stimuli
Time Frame: 7 days, starting on day 1.
Number of intrusive mental images of phobic stimuli recorded by participants in a diary, daily (morning, afternoon, evening and night) for 7 days. This measure is included as a manipulation check.
7 days, starting on day 1.
Demand questions
Time Frame: Day 1
Two questions asking participants' to appreciate the emotional impact of producing mental imagery versus focusing on the verbal aspects of phobic situations used in the experimental procedure. This measure is included as a manipulation check.
Day 1
The Plymouth Sensory Imagery Questionnaire (Psi-Q)
Time Frame: Day 1
The Psi-Q is a self-rated measure of vividness of imagery across different sensory modalities. Higher scores indicate higher levels of vividness (range, total score 0 - 70).
Day 1

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 11, 2017

Primary Completion (Actual)

February 14, 2018

Study Completion (Actual)

February 22, 2018

Study Registration Dates

First Submitted

May 24, 2019

First Submitted That Met QC Criteria

May 29, 2019

First Posted (Actual)

May 31, 2019

Study Record Updates

Last Update Posted (Actual)

May 31, 2019

Last Update Submitted That Met QC Criteria

May 29, 2019

Last Verified

May 1, 2019

More Information

Terms related to this study

Other Study ID Numbers

  • 2017/419

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Individuals With Fear of Spiders

Clinical Trials on Imaginal exposure

Subscribe